Pfizer Inc. (NYSE:PFE) Shares Purchased by Bank of Marin

Bank of Marin raised its holdings in Pfizer Inc. (NYSE:PFE) by 67.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,100 shares of the biopharmaceutical company’s stock after purchasing an additional 5,670 shares during the quarter. Bank of Marin’s holdings in Pfizer were worth $374,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of PFE. Swedbank AB increased its holdings in shares of Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after buying an additional 37,636 shares during the last quarter. United Bank boosted its position in Pfizer by 3.7% in the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after buying an additional 1,277 shares during the period. Thrivent Financial for Lutherans boosted its position in Pfizer by 14.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 846,582 shares of the biopharmaceutical company’s stock valued at $24,500,000 after buying an additional 107,346 shares during the period. Meeder Advisory Services Inc. lifted its position in shares of Pfizer by 2.5% during the 3rd quarter. Meeder Advisory Services Inc. now owns 61,784 shares of the biopharmaceutical company’s stock worth $1,788,000 after purchasing an additional 1,503 shares during the last quarter. Finally, Joseph Group Capital Management lifted its position in shares of Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 771 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 0.06% of the stock is owned by company insiders.

Pfizer Stock Up 1.0 %

Shares of NYSE:PFE opened at $26.31 on Wednesday. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company’s fifty day moving average is $26.21 and its 200-day moving average is $27.09. The company has a market capitalization of $149.09 billion, a PE ratio of 18.66, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period last year, the company posted $0.10 EPS. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on PFE. Citigroup cut their price target on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Truist Financial reduced their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Finally, UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.